Reading NUVL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUVL free→Reading NUVL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUVL free→QuarterlyIQ Insights · NUVL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “ Company ” or “ Nuvalent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited co…
Other Events. On June 9, 2026, Ultimate Parent issued a press release announcing the execution of the Merger Agreement. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the fil…
Results of Operations and Financial Condition. On May 7, 2026, Nuvalent, Inc. announced its financial results for the quarter ended March 31, 2026, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18…
Results of Operations and Financial Condition. On February 26, 2026, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purp…
Results of Operations and Financial Condition. On January 12, 2026, Nuvalent, Inc. (the “Company”) issued a press release in which it reported a preliminary estimate that, as of December 31, 2025, it had approximately $1.4 billion in cash, cash equivalents and marketable securities. This amount is a preliminary, unaudited estimate only as of January 12, 2026, is subject to completion of the Company’s year-end financial closing procedures that could result in changes to the amount, and does no…
Other Events. Nuvalent, Inc. (the “Company” or “Nuvalent”) is aware of the announcement this morning by Royalty Pharma plc (“Royalty Pharma”) that it has acquired a preexisting royalty interest in Nuvalent’s neladalkib and zidesamtinib investigational product candidates from an undisclosed third party for up to $315 million. Information regarding Nuvalent’s revenue share agreement with its scientific founder is available in Note 10 of Nuvalent’s financial statements contained in Nuvalent’s An…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On December 9, 2025, Matthew Shair, Ph.D., a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of his decision to resign from the Board and from all committees of the Board on which he serves, effective immediately. Dr. Shair’s decision to resign was not as a result of any d…
Entry into a Material Definitive Agreement. On November 18, 2025, Nuvalent, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters (the “Underwriters”), and Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P., each as a selling stockholder (together, the “Selling Stockholders”)…
Other Events. On November 18, 2025, the Company issued a press release (the “Press Release”) announcing the pricing of the Offering. A copy of the Press Release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company estimates that the net proceeds to the Company from the Offering, together with the Company’s existing cash, cash equivalents and marketable securities, will enable it to fund its operating expenses and capital expend…
Results of Operations and Financial Condition. On October 30, 2025, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of S…
Results of Operations and Financial Condition. On August 7, 2025, Nuvalent, Inc. announced its financial results for the quarter ended June 30, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 18, 2025, in accordance with the recommendation of the Nominating and Corporate Governance Committee (“NCG Committee”) of the Board of Directors (the “Board”) of Nuvalent, Inc. (the “Company”), the Board elected Christy J. Oliger as a member of the Board, effective immediately. Ms. Oliger was elected to serve as a Class III director of the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2025, Emily Conley, a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of her decision to resign from the Board and from all committees of the Board on which she serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders. Ms. Conley’s decision to re…
Results of Operations and Financial Condition. On May 8, 2025, Nuvalent, Inc. announced its financial results for the quarter ended March 31, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 11, 2025, D. Gary Gilliland, M.D., Ph.D., a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of his decision to resign from the Board and from all committees of the Board on which he serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders. It is ex…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.